DOPTELET: payments to doctors
Payments that named DOPTELET as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.7M
- Providers
- 9,563
- Transactions
- 31,030
- Average per transaction
- $216
The per-transaction average — $216 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,563 providers the average total is $700, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Dova Pharmaceuticals | $2,754,543 | 41.1% |
| SOBI, Inc | $2,401,726 | 35.9% |
| Sobi, Inc | $1,319,596 | 19.7% |
| Swedish Orphan Biovitrum AB | $115,666 | 1.7% |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | $103,982 | 1.6% |